Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 20, Pages 5046
Publisher
MDPI AG
Online
2022-10-17
DOI
10.3390/cancers14205046
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
- (2022) Desislava Yanakieva et al. mAbs
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
- (2022) Natalia Colomar-Carando et al. Cancer Immunology Research
- Biology and Clinical Relevance of HCMV-Associated Adaptive NK Cells
- (2022) Fei Gao et al. Frontiers in Immunology
- When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer
- (2022) Mohamed S. Hasim et al. Science Advances
- Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
- (2022) Pratibha Pandey et al. Pharmaceuticals
- Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia
- (2022) Han Dong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity
- (2022) Nicole Kirchhammer et al. Science Translational Medicine
- PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells
- (2022) Cecilia Pesini et al. OncoImmunology
- Resident Immune Cells of the Liver in the Tumor Microenvironment
- (2022) Yunjie Lu et al. Frontiers in Oncology
- Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives
- (2022) Eugenia Cella et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Natural Killer Cells: From Innate to Adaptive Features
- (2021) Adriana M. Mujal et al. Annual Review of Immunology
- Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
- (2021) Giuseppe Curigliano et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
- (2021) Kai Tang et al. Journal of Hematology & Oncology
- LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC
- (2021) A. Martinez-Marti et al. ANNALS OF ONCOLOGY
- Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments
- (2021) Olivier Demaria et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer
- (2021) Max Backman et al. JOURNAL OF PATHOLOGY
- 123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
- (2021) D.A. Colevas et al. ANNALS OF ONCOLOGY
- LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC
- (2021) B.C. Cho et al. ANNALS OF ONCOLOGY
- Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
- (2021) Glenn J. Hanna et al. CLINICAL CANCER RESEARCH
- A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
- (2021) David Yashar et al. LEUKEMIA & LYMPHOMA
- A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment
- (2021) Jie Wen et al. Scientific Reports
- Tissue Determinants of Human NK Cell Development, Function, and Residence
- (2020) Pranay Dogra et al. CELL
- Phase 1 Study of Epacadostat in Combination With Atezolizumab for Patients With Previously Treated Advanced Non‐Small Cell Lung Cancer
- (2020) Matthew D. Hellmann et al. INTERNATIONAL JOURNAL OF CANCER
- Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
- (2020) Selene Ottonello et al. Frontiers in Immunology
- Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
- (2020) Aviad Ben-Shmuel et al. Frontiers in Immunology
- TIM‐3 and CEACAM1 do not interact in cis and in trans
- (2020) Annika De Sousa Linhares et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Elucidation of S-Allylcysteine Role in Inducing Apoptosis by Inhibiting PD-L1 Expression in Human Lung Cancer Cells
- (2020) Fahad Khan et al. Anti-Cancer Agents in Medicinal Chemistry
- IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
- (2020) Joe-Marc Chauvin et al. CLINICAL CANCER RESEARCH
- A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies
- (2020) Philippe Armand et al. LEUKEMIA
- NK cells and ILCs in tumor immunotherapy
- (2020) Simona Sivori et al. MOLECULAR ASPECTS OF MEDICINE
- Natural killer cells in cancer biology and therapy
- (2020) Song-Yang Wu et al. Molecular Cancer
- TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better
- (2020) Gabriella Pietra et al. CLINICAL CANCER RESEARCH
- Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia
- (2020) Melissa M. Berrien-Elliott et al. Cancer Discovery
- TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation
- (2020) Tram N. Dao et al. Cancers
- NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis
- (2020) Sarah Nersesian et al. Translational Oncology
- The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
- (2019) Fernando Souza-Fonseca-Guimaraes et al. TRENDS IN IMMUNOLOGY
- TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
- (2019) Yujia Zheng et al. Journal of Translational Medicine
- Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
- (2019) Rachael M. Zemek et al. Science Translational Medicine
- PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
- (2019) Silvia Pesce et al. Frontiers in Immunology
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
- (2019) Martine Bagot et al. LANCET ONCOLOGY
- Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation
- (2019) Leah Schmidt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phenotypic and Functional Analysis of Human NK Cell Subpopulations According to the Expression of FcεRIγ and NKG2C
- (2019) Kyung Hwan Kim et al. Frontiers in Immunology
- Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
- (2018) Frank Vari et al. BLOOD
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
- (2018) Jan P. Böttcher et al. CELL
- Epithelial-mesenchymal transition leads to NK cell–mediated metastasis-specific immunosurveillance in lung cancer
- (2018) Peter J. Chockley et al. JOURNAL OF CLINICAL INVESTIGATION
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells
- (2018) Quirin Hammer et al. NATURE IMMUNOLOGY
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
- (2018) Norbert Vey et al. Oncotarget
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- Not All Immune Checkpoints Are Created Equal
- (2018) Annika De Sousa Linhares et al. Frontiers in Immunology
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Human CD96 correlates to NK cell exhaustion and predicts the prognosis of human hepatocellular carcinoma
- (2018) Haoyu Sun et al. HEPATOLOGY
- Emerging insights into human health and NK cell biology from the study of NK cell deficiencies
- (2018) Emily M. Mace et al. IMMUNOLOGICAL REVIEWS
- The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
- (2018) Giulia Mazzaschi et al. LUNG CANCER
- Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells
- (2018) Xiu-Man Zhou et al. Frontiers in Immunology
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- Recent progress in GM-CSF-based cancer immunotherapy
- (2017) Wan-Lun Yan et al. Immunotherapy
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1
- (2017) Nina Chi Sabins et al. JOURNAL OF IMMUNOLOGY
- Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
- (2017) Y Liu et al. ONCOGENE
- Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
- (2016) M. Carlsten et al. CLINICAL CANCER RESEARCH
- Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes
- (2016) L. K. Mackay et al. SCIENCE
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
- (2016) Asma Beldi-Ferchiou et al. Oncotarget
- Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
- (2016) Joerg U. Schmohl et al. Oncotarget
- Human Circulating and Tissue-Resident CD56bright Natural Killer Cell Populations
- (2016) Janine E. Melsen et al. Frontiers in Immunology
- The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
- (2015) Zhenxin Wang et al. IMMUNOLOGICAL INVESTIGATIONS
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CD56brightPerforinlow Noncytotoxic Human NK Cells Are Abundant in Both Healthy and Neoplastic Solid Tissues and Recirculate to Secondary Lymphoid Organs via Afferent Lymph
- (2014) P. Carrega et al. JOURNAL OF IMMUNOLOGY
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- NK Cell Phenotypic Modulation in Lung Cancer Environment
- (2014) Shi Jin et al. PLoS One
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
- (2012) L. C. Ndhlovu et al. BLOOD
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
- (2012) S. Gill et al. BLOOD
- Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
- (2011) S. Platonova et al. CANCER RESEARCH
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4
- (2010) Seng-Ryong Woo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now